Waldenström Macroglobulinemia, a type of non-Hodgkin’s lymphoma, is commonly prescribed first-line treatment with rituximab or ibrutinib. A retrospective observational administrative claims database study (2014-2019) assessed these agents as first-line treatment in Medicare Fee-For-Service beneficiaries. Ibrutinib was associated with significantly longer time to next treatment.